Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11299492
JAK kinase inhibitor compounds for treatment of respiratory disease
granted -
US 11298441
Biodegradable biomimetics of growth plate cartilage for the treatment of physeal injuries
granted -
US 11298424
Non-ionic and thermoresponsive diblock copolypeptide hydrogels for delivery of molecules and cells
granted -
US 11298350
Subcutaneous delivery of polymer conjugates of therapeutics agents
granted -
US 11298430
Magnetic nanocomposite compositions
granted -
US 11298309
Topical silk compositions and methods of using
granted -
US 11299515
Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic
granted -
US 11299533
Purification of factor VIII subspecies
granted -
WO 2022074143
DÉRIVÉS DE BENZO[H]QUINAZOLIN-4-AMINE ET DE THIÉNO[3,2-H]QUINAZOLIN-4-AMINE POUR LE TRAITEMENT DU CANCER
granted -
TW 202214258
Compounds and methods for treating fungal infections
granted -
US 11306104
Solid state forms of Relugolix
granted -
US 11306077
Compounds, compositions and methods
granted -
US 11306123
Heterotandem bicyclic peptide complex
granted -
US 11306150
Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
granted -
US 11304904
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 11304895
Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 11304879
Adhesive composition for dental use
granted -
US 11304935
Use of I-BRD9 or derivatives thereof in preparing anti-epileptic drugs
granted -
US 11304926
Application of transient receptor potential cation channel TRPV3 in developing drug for preventing or treating psoriasis
granted -
US 11304914
Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted -
US 11304911
Compositions and methods for organ specific delivery of nucleic acids
granted -
US 11304950
Methods for treating testicular and ovarian adrenal rest tumors
granted -
US 11304959
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 11304988
Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)
granted -
US 11306115
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 11304980
Restimulation of cryopreserved tumor infiltrating lymphocytes
granted -
US 11304996
Yeast-based immunotherapy and type I interferon sensitivity
granted -
US 11305002
Compositions and treatments for Haemophilus influenzae
granted -
US 11305022
Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
granted -
US 11306088
CXCR4 inhibitors and uses thereof
granted -
US 11306095
Use of pteridinone derivative serving as EGFR inhibitor
granted -
US 11306155
Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
granted -
US 11304993
Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
granted -
US 11306098
Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
granted -
US 11306288
Methods for preparing therapeutically active cells using microfluidics
granted -
US 11306135
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11306132
HLA class II-restricted T cell receptors against mutated RAS
granted -
US 11306122
Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor
granted -
US 11306121
Composition for muscle relaxation
granted -
US 11306130
PAR3 mimetic peptides and uses thereof
granted -
US 11305009
Recombinant virus with diminished latency and methods of using same
granted -
US 11304979
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11304916
Methods and compositions for the treatment of Shiga Toxicosis
granted -
US 11306131
T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage
granted -
US 11306144
B7-H4 antibodies and methods of use thereof
granted -
US 11306148
Anti-NPR1 antibodies and uses thereof
granted -
US 11306149
Anti-CD40 antibodies and uses thereof
granted -
US 11306287
Method of generating skeletal muscle stem cells from pluripotent cells
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.